{"id":"https://openalex.org/W3179720171","doi":"https://doi.org/10.1089/dia.2021.0108","title":"Immunogenicity of the novel glucagon analog dasiglucagon: Results of a dedicated immunogenicity trial in type 1 diabetes","display_name":"Immunogenicity of the novel glucagon analog dasiglucagon: Results of a dedicated immunogenicity trial in type 1 diabetes","publication_year":2021,"publication_date":"2021-07-12","ids":{"openalex":"https://openalex.org/W3179720171","doi":"https://doi.org/10.1089/dia.2021.0108","mag":"3179720171","pmid":"https://pubmed.ncbi.nlm.nih.gov/34252289"},"language":"en","primary_location":{"id":"doi:10.1089/dia.2021.0108","doi":"https://doi.org/10.1089/dia.2021.0108","is_oa":true,"landing_page_url":"https://doi.org/10.1089/dia.2021.0108","pdf_url":null,"source":{"id":"https://openalex.org/S67495602","display_name":"Diabetes Technology & Therapeutics","issn_l":"1520-9156","issn":["1520-9156","1557-8593"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Technology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1089/dia.2021.0108","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023877066","display_name":"Thomas Rudolf Pieber","orcid":"https://orcid.org/0000-0003-3554-0405","observed_orcids":["https://orcid.org/0000-0003-3554-0405"]},"institutions":[{"id":"https://openalex.org/I13402291","display_name":"Joanneum Research","ror":"https://ror.org/049bdss47","country_code":"AT","type":"facility","lineage":["https://openalex.org/I13402291"]},{"id":"https://openalex.org/I202276237","display_name":"Medical University of Graz","ror":"https://ror.org/02n0bts35","country_code":"AT","type":"education","lineage":["https://openalex.org/I202276237"]}],"countries":["AT"],"is_corresponding":true,"raw_author_name":"Thomas R. Pieber","raw_affiliation_strings":["Joanneum Research GmbH, HEALTH - Institute for Biomedicine and Health Sciences, Graz, Austria;","Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Joanneum Research GmbH, HEALTH - Institute for Biomedicine and Health Sciences, Graz, Austria;","institution_ids":["https://openalex.org/I13402291"]},{"raw_affiliation_string":"Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Austria","institution_ids":["https://openalex.org/I202276237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016743189","display_name":"Olubukola Ajala","orcid":"https://orcid.org/0000-0002-3699-9157","observed_orcids":["https://orcid.org/0000-0002-3699-9157"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Olubukola Ajala","raw_affiliation_strings":["LMC, Calgary, Canada;","LMC, Calgary, AB, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LMC, Calgary, Canada;","institution_ids":[]},{"raw_affiliation_string":"LMC, Calgary, AB, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044805383","display_name":"Oren Steen","orcid":"https://orcid.org/0000-0001-8604-6891","observed_orcids":["https://orcid.org/0000-0001-8604-6891"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Oren Steen","raw_affiliation_strings":["LMC, Toronto, Canada;","LMC, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LMC, Toronto, Canada;","institution_ids":[]},{"raw_affiliation_string":"LMC, Toronto, ON, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109925049","display_name":"Dominik B. Dahl","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dominik Dahl","raw_affiliation_strings":["Diabeteszentrum, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabeteszentrum, Hamburg, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108754367","display_name":"Lone Hansen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096064","display_name":"Zealand Pharma (Denmark)","ror":"https://ror.org/00tf97v72","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210096064"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Lone Hansen","raw_affiliation_strings":["Zealand Pharma a/s, 3549, Glostrup, Denmark;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Zealand Pharma a/s, 3549, Glostrup, Denmark;","institution_ids":["https://openalex.org/I4210096064"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088310334","display_name":"Ramin Tehranchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096064","display_name":"Zealand Pharma (Denmark)","ror":"https://ror.org/00tf97v72","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210096064"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Ramin Tehranchi","raw_affiliation_strings":["Zealand Pharma a/s, 3549, Glostrup, Denmark;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Zealand Pharma a/s, 3549, Glostrup, Denmark;","institution_ids":["https://openalex.org/I4210096064"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5023877066"],"corresponding_institution_ids":["https://openalex.org/I13402291","https://openalex.org/I202276237"],"apc_list":null,"apc_paid":null,"fwci":0.3424,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.53760138,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":95},"biblio":{"volume":"23","issue":"11","first_page":"773","last_page":"776"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.7890999913215637,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.7890999913215637,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.07150000333786011,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasiglucagon","display_name":"dasiglucagon","score":1.0},{"id":"https://openalex.org/keywords/glucagon-analog","display_name":"glucagon analog","score":0.6710000038146973},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9319999814033508},{"id":"https://openalex.org/keywords/type-1-diabetes","display_name":"type 1 diabetes","score":0.8820000290870667},{"id":"https://openalex.org/keywords/antidrug-antibodies","display_name":"antidrug antibodies","score":0.8539999723434448},{"id":"https://openalex.org/keywords/severe-hypoglycemia","display_name":"severe hypoglycemia","score":0.8989999890327454},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.7039999961853027},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8109999895095825},{"id":"https://openalex.org/keywords/injection-site-reactions","display_name":"injection site reactions","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.9397729635238647},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9157376289367676},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.6593241691589355},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5808062553405762},{"id":"https://openalex.org/C2781232474","wikidata":"https://www.wikidata.org/wiki/Q124407","display_name":"Type 1 diabetes","level":3,"score":0.549488365650177},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.5476949214935303},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5304153561592102},{"id":"https://openalex.org/C2776390293","wikidata":"https://www.wikidata.org/wiki/Q2035485","display_name":"Subcutaneous injection","level":2,"score":0.49400073289871216},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.49112769961357117},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43952298164367676},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.43931812047958374},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.42577216029167175},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41291481256484985},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.40706706047058105},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.35765713453292847},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.316024512052536},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.23440048098564148},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003922","descriptor_name":"Diabetes Mellitus, Type 1","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005934","descriptor_name":"Glucagon","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1089/dia.2021.0108","doi":"https://doi.org/10.1089/dia.2021.0108","is_oa":true,"landing_page_url":"https://doi.org/10.1089/dia.2021.0108","pdf_url":null,"source":{"id":"https://openalex.org/S67495602","display_name":"Diabetes Technology & Therapeutics","issn_l":"1520-9156","issn":["1520-9156","1557-8593"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Technology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:34252289","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34252289","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes technology & therapeutics","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1089/dia.2021.0108","doi":"https://doi.org/10.1089/dia.2021.0108","is_oa":true,"landing_page_url":"https://doi.org/10.1089/dia.2021.0108","pdf_url":null,"source":{"id":"https://openalex.org/S67495602","display_name":"Diabetes Technology & Therapeutics","issn_l":"1520-9156","issn":["1520-9156","1557-8593"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-2","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Technology & Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":2,"referenced_works":["https://openalex.org/W2076399332","https://openalex.org/W3155770573"],"related_works":["https://openalex.org/W3155770573","https://openalex.org/W3157453693","https://openalex.org/W3178788621","https://openalex.org/W2781395153","https://openalex.org/W3174763299","https://openalex.org/W4317871404","https://openalex.org/W3173493694","https://openalex.org/W4214835119","https://openalex.org/W7217554397","https://openalex.org/W2335878298"],"abstract_inverted_index":{"Dasiglucagon":[0],"is":[1,7],"a":[2,70,82],"next-generation":[3],"glucagon":[4,66],"analogue":[5],"that":[6],"stable":[8],"in":[9,37,119],"aqueous":[10],"formulation.":[11],"This":[12],"dedicated":[13],"immunogenicity":[14,30,97],"trial":[15,73,121,128],"to":[16,27,51,69],"support":[17],"use":[18],"as":[19,105],"rescue":[20],"treatment":[21],"for":[22,78,87,136,146],"severe":[23],"hypoglycemia":[24],"was":[25,103],"conducted":[26],"evaluate":[28],"the":[29,95,99,147],"of":[31,35,45,57,89,127],"repeated":[32],"subcutaneous":[33,54],"doses":[34,56,126],"dasiglucagon":[36,61],"subjects":[38,47,137],"with":[39,81],"type":[40],"1":[41],"diabetes.":[42],"A":[43],"total":[44],"112":[46],"were":[48,76,134,141],"randomized":[49],"1:1":[50],"receive":[52],"three":[53,123],"weekly":[55,125],"either":[58],"0.6":[59],"mg":[60,64],"or":[62,111],"1.0":[63],"recombinant":[65],"(GlucaGen\u00ae)":[67],"according":[68],"double-blind":[71],"parallel-group":[72],"design.":[74],"Subjects":[75],"followed":[77],"15":[79],"weeks,":[80],"multitiered":[83],"testing":[84],"approach":[85],"planned":[86],"assessment":[88],"antidrug":[90],"antibody":[91],"(ADA)":[92],"formation.":[93],"For":[94],"primary":[96],"endpoint,":[98],"overall":[100],"ADA":[101,113],"incidence":[102],"zero,":[104],"no":[106,142],"subject":[107],"demonstrated":[108],"any":[109,116],"treatment-induced":[110],"treatment-boosted":[112],"response":[114],"at":[115],"time":[117],"point":[118],"this":[120],"involving":[122],"consecutive":[124],"drug.":[129],"No":[130],"injection":[131],"site":[132],"reactions":[133],"reported":[135],"receiving":[138],"dasiglucagon.":[139],"There":[140],"unexpected":[143],"safety":[144],"findings":[145],"trial.":[148]},"counts_by_year":[{"year":2022,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2021-07-19T00:00:00"}